Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
Diabetes Obes Metab
; 22(3): 458-462, 2020 03.
Article
in En
| MEDLINE
| ID: mdl-31486230
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Symporters
/
Diabetes Mellitus, Type 2
/
Dipeptidyl-Peptidase IV Inhibitors
/
Sodium-Glucose Transporter 2 Inhibitors
Type of study:
Clinical_trials
/
Observational_studies
Limits:
Humans
Language:
En
Year:
2020
Type:
Article